COXIGET Capsule Ref.[115702] Active ingredients: Celecoxib

Source: Registered Drug Product Database (NG)  Publisher: Getz Pharma (Pvt.) Limited, 29-30/27, Korangi Industrial Area Karachi 74900, Pakistan, Tel: (92-21) 111-111-511, Fax: (92-21) 5057592 Drug product manufacturer: Getz Pharma (Pvt.) Limited, 29-30/27, Korangi Industrial Area Karachi 74900, Pakistan, Tel: (92-21) 111-111-511, Fax: (92-21) 5057592

4.1. Therapeutic indications

COXIGET (Celecoxib) is indicated:

  • For relief of the signs and symptoms of osteoarthritis.
  • For relief of the signs and symptoms of rheumatoid arthritis in adults.
  • For the symptomatic relief in the treatment of ankylosing spondylitis.
  • For relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients 2 years and older.
  • For the management of acute pain in adults especially in post-operative pain.
  • For the treatment of primary dysmenorrhea.
  • To reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP), as an adjunct to usual care (e.g., endoscopic surveillance, surgery).

4.2. Posology and method of administration

For osteoarthritis and rheumatoid arthritis, the lowest dose of COXIGET (Celecoxib) should be sought for each patient. These doses can be given without regard to timing of meals. COXIGET (Celecoxib) can be taken with or without food.

Osteoarthritis

For relief of the signs and symptoms of osteoarthritis the recommended oral dose is 200 mg per day administered as a single dose or as 100 mg twice daily. If necessary a dose of 200 mg twice daily may be used. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.

Rheumatoid arthritis

For relief of the signs and symptoms of rheumatoid arthritis the recommended oral dose is 100 mg to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.

Ankylosing spondylitis

The recommended daily dose is 200 mg taken once daily or in two divided doses. Dose can be increased to 400 mg once daily or in two divided doses in patients with insufficient relief of symptoms. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.

Juvenile rheumatoid arthritis

For the relief of the signs and symptoms of JRA the recommended oral dose for pediatric patients (age 2 years and older) is based on weight. For patients >10kg to <25kg the recommended dose is 50 mg twice daily. For patients >25kg the recommended dose is 100 mg twice daily. For patients who have difficulty swallowing capsules, the contents of a COXIGET (Celecoxib) capsule can be added to apple sauce. The entire capsule contents are carefully emptied onto a level teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled capsule contents on applesauce are stable for up to 6 hours under refrigerated conditions (2°C-8°C).

Management of acute pain and treatment of primary dysmenorrhea

The recommended dose of COXIGET (Celecoxib) is 400 mg initially, followed by an additional 200 mg dose if needed on the first day. On subsequent days, the recommended dose is 200 mg twice daily as needed or 400 mg once daily.

Familial adenomatous, polyposis (FAP)

Usual medical care for FAP patients should be continued while on COXIGET (Celecoxib). To reduce the number of adenomatous colorectal polyps in patients with FAP, the recommended oral dose is 400 mg twice per day to be taken with food.

Elderly patients (>65 years)

As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50kg.

Hepatic insufficient patients

The daily recommended dose of COXIGET (Celecoxib) capsules in patients with moderate hepatic impairment (Child-Pugh Class B) should be reduced by approximately 50%.

Poor metabolizers of CYP2C9 substrates

Consideration should be given to starting treatment at half the lowest recommended dose in these patients. Consideration should also be given to using alternative management in JRA patients who are poor metabolizers.

4.9. Overdose

Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose. Patients should be managed by symptomatic and supportive care following an NSAID overdose. Monitor patients for signs and symptoms of gastrointestinal ulceration and/or hemorrhage. Monitor serum electrolytes, renal function and urinalysis after significant overdose.

6.3. Shelf life

3 years.

The expiration date refers to the product correctly stored in the required conditions.

6.4. Special precautions for storage

Do not store above 30°C.

Protect from sunlight and moisture.

6.5. Nature and contents of container

COXIGET Capsules 200 mg are available in Alu-Alu blister packs of 2x10's capsules in a unit carton along with the package insert.

COXIGET Capsules 400 mg are available in Alu-Alu blister packs of 2x10's capsules in a unit carton along with the package insert.

6.6. Special precautions for disposal and other handling

Keep out of reach of children.

To be sold on prescription of a registered medical practitioner only.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.